2017年度　業績

循環器グループ

  1. Ishikawa S, Noma T, Fu HY, Matsuzaki T, Ishizawa M, Ishikawa K, Murakami K, Nishimoto N, Nishiyama A, Minamino T. Apoptosis inhibitor of macrophage depletion decreased M1 macrophage accumulation and the incidence of cardiac rupture after myocardial infarction in mice. PLoSOne. 2017;12(11):e0187894
  2. Kawakami R, Matsumoto I, Shiomi M, Kurozumi M, Miyake Y, Ishizawa M, Ishikawa K, Murakami K, Noma T, Takagi Y, Nishimoto N, Minamino T. Role of the Low-Density Lipoprotein-Cholesterol/High-Density Lipoprotein-Cholesterol Ratio in Predicting Serial Changes in the Lipid Component of Coronary Plaque. Circ J. 2017;81(10):1439-1446
  3. Asanuma H, Sanada S, Yoshitomi T, Sasaki H, Takahama H, Ihara M, Takahama H, Shinozaki Y, Mori H, Asakura M, Nakano A, Sugimachi M,Asano Y, Minamino T, Takashima S, Nagasaki Y, Kitakaze M. Novel Synthesized Radical-Containing Nanoparticles Limit Infarct Size Following Ischemia and Reperfusion in Canine Hearts. Cardiovasc Drugs Ther. 2017:31(5-6): 501-510
  4. Okamoto A, Asai T, Hirai Y, Shimizu K, Koide H, Minamino T, Oku N. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer. Mol Pharm. 2018.
  5. Minamino T, Higo S, Araki R, Hikoso S, Nakatani D, Suzuki H, Yamada T, Okutsu M, Yamamoto K, Fujio Y, Ishida Y, Ozawa T, Kato K, Toba K,Aizawa Y, Komuro I; EPO-AMI-II Investigators. Okutsu M, Yamamoto K, Fujio Y, Ishida Y, Ozawa T, Kato K, Toba K, Aizawa Y, Komuro I Low-Dose Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction (EPO-AMI-II) – A Randomized Controlled Clinical Trial. Circ J. 2018
  6. Kawakami R, Nozato Y, Nakagami H, Ikeda Y, Shimamura M, Yoshida S, Sun J, Kawano T, Takami Y, Noma T, Rakugi H, Minamino T, Morishita R. Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice. PLoS One. 2018;13(2):e0191895

腎臓グループ

  1. Ozaki T, Sofue T, and Kuroda. Severe glyphosate-surfactant intoxication successfully treated with continuous hemodiafiltration and direct hemoperfusion: case report. Ther Apher Dial. 2017; 21(3): 296-297
  2. Fujita T, Sofue T, Moritoki M, Nishijima Y, Tokuhara Y, Wakisaka H, Matsunaga T, Kushida Y, Haba R, Ohsaki H. Urinary WT1 Positive Cells as a Non-invasive Biomarker of Crescent Formation. Cytopathology. 2017;28(6):524-530
  3. Sofue T, Kushida Y, Ozaki T, Moritoki M, Nishijima Y, Ohsaki H, Ueda N, Kakehi Y, Nishiyama A, Minamino T. Tubular cell senescence in the donated kidney predicts allograft functions, but not donor remnant kidney functions, in living donor kidney transplantation. Am J Nephrol. 2018:47(1):8-17
  4. Tsuji Y, Nozu K, Sofue T, Nakanishi K, Yamamura T, Minamikawa S,Nozu Y, Kaito H, Fujimura J, Horinouchi T, Morisada N, Matsuo M,Iijima K. Detection of a splice site variant in a patient with glomerulopathy and fibronectin deposits. Nephron. 2018;138(2):166-171
  5. Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamazaki K, Sofue T, Kano T, Suzuki Y. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1 oriented pathogenesis. Kidney Int. 2018;93(3):700-705.